Risk factors for recurrence of giant cell tumours of bone

被引:28
|
作者
Siddiqui, Mashfiqul A. [1 ]
Seng, Chusheng [1 ]
Tan, Mann Hong [1 ]
机构
[1] Singapore Gen Hosp, Dept Orthopaed Surg, Singapore 169608, Singapore
来源
JOURNAL OF ORTHOPAEDIC SURGERY | 2014年 / 22卷 / 01期
关键词
giant cell tumor of bone; neoplasm recurrence; local;
D O I
10.1177/230949901402200127
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Purpose. To determine the risk factors for recurrence of giant cell tumours (GCTs) of bone. Methods. Medical records of 29 men and 29 women (mean age, 34 years) treated for primary (n=53) or recurrent (n=5) GCTs of bone and followed up for a mean of 40.2 months were reviewed. The tumours were located in the distal femur (n=18), proximal tibia (n=10), proximal femur (n=8), distal radius (n=7), proximal fibula (n=4), distal ulna (n=3), calcaneum (n=3), sacrum (n=2), vertebra (n=1), metatarsal (n=1), and distal humerus (n=1). 26 patients had pathological fractures, 12 had cortical break, and 20 had neither. The Campanacci grades of the tumours were I (n=1), II (n=18), and III (n=33); the grades of the remaining 6 tumours were unknown because radiographs were unavailable. The Enneking stages of the tumours were 1 (n=51), 2 (n=6), and 3 (n=1). Treatment included curettage and cementation (n=29), curettage, cementation, and adjuvant treatment with distilled water or liquid nitrogen for bones without fracture (n=18), wide resection for extensive soft tissue involvement (n=9), and amputation (n=2) for a recurrent GCT of the distal femur and a primary GCT of the calcaneus. Reconstruction included cementation (n=27), bone grafting (n=7), cementation/bone grafting with internal fixation (n=14), reconstruction with endoprosthesis (n=3), and none (n=7). Results. 19 patients had recurrence after a mean of 23.1 months. The overall recurrence-free survival at years 1, 2, and 3 were 86%, 79%, and 72%, respectively. Recurrence did not correlate with patient age (p=0.20), primary or recurrent tumour at presentation (p=0.12), Campanacci grade (p=0.10), Enneking stage (p=0.54), or presence of pathological fracture (p=0.28). Compared to GCTs at other locations, GCTs in the proximal tibia were more likely to recur (27% vs. 60%, p=0.04). Conclusion. GCTs of the proximal tibia are more likely to recur than those at other locations.
引用
收藏
页码:108 / 110
页数:3
相关论文
共 50 条
  • [41] Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone
    Sano, Kei
    Suehara, Yoshiyuki
    Okubo, Taketo
    Sasa, Keita
    Kurihara, Taisei
    Akaike, Keisuke
    Kubota, Daisuke
    Torigoe, Tomoaki
    Hasegawa, Nobuhiko
    Ishii, Midori
    Nakamura, Yasuhiro
    Kim, Youngji
    Takagi, Tatsuya
    Kaneko, Kazuo
    Hayashi, Takuo
    Saito, Tsuyoshi
    JOURNAL OF ORTHOPAEDIC SURGERY, 2020, 28 (02)
  • [42] Late Local Recurrence of Bone Giant Cell Tumors Associated with an Increased Risk for Malignant Transformation
    Tsukamoto, Shinji
    Righi, Alberto
    Mavrogenis, Andreas F.
    Akahane, Manabu
    Honoki, Kanya
    Tanaka, Yasuhito
    Donati, Davide Maria
    Errani, Costantino
    CANCERS, 2021, 13 (14)
  • [43] Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?
    Scoccianti, Guido
    Totti, Francesca
    Scorianz, Maurizio
    Baldi, Giacomo
    Roselli, Giuliana
    Beltrami, Giovanni
    Franchi, Alessandro
    Capanna, Rodolfo
    Campanacci, Domenico Andrea
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2018, 476 (09) : 1783 - 1790
  • [44] Risk factors of fracture following curettage for bone giant cell tumors of the extremities
    Shinji Tsukamoto
    Andreas F. Mavrogenis
    Manabu Akahane
    Kanya Honoki
    Akira Kido
    Yasuhito Tanaka
    Davide Maria Donati
    Costantino Errani
    BMC Musculoskeletal Disorders, 23
  • [45] Risk factors of fracture following curettage for bone giant cell tumors of the extremities
    Tsukamoto, Shinji
    Mavrogenis, Andreas F.
    Akahane, Manabu
    Honoki, Kanya
    Kido, Akira
    Tanaka, Yasuhito
    Donati, Davide Maria
    Errani, Costantino
    BMC MUSCULOSKELETAL DISORDERS, 2022, 23 (01)
  • [46] GIANT CELL TUMOURS OF TENDON SHEATH OF HAND: CAUSES AND STRATEGIES TO PREVENT RECURRENCE
    Jalgaonkar, Azal
    Dhinsa, Baljinder
    Cottam, Howard
    Mani, Ganapathyraman
    JOURNAL OF HAND SURGERY-ASIAN-PACIFIC VOLUME, 2011, 16 (02): : 149 - 154
  • [47] Giant cell tumor of tendon sheath in the hand: analysis of risk factors for recurrence in 50 cases
    Hakan Ozben
    Tamer Coskun
    BMC Musculoskeletal Disorders, 20
  • [48] Giant cell tumor of tendon sheath in the hand: analysis of risk factors for recurrence in 50 cases
    Ozben, Hakan
    Coskun, Tamer
    BMC MUSCULOSKELETAL DISORDERS, 2019, 20 (01)
  • [49] Recurrence of giant cell tumor of bone: The role of MRI in diagnosis
    Waldman, BJ
    Zerhouni, EA
    Frassica, FJ
    ORTHOPEDICS, 1997, 20 (01) : 67 - 69
  • [50] MALIGNANCY, AGGRESSIVENESS, AND RECURRENCE IN GIANT-CELL TUMOR OF BONE
    SANERKIN, NG
    CANCER, 1980, 46 (07) : 1641 - 1649